Teva Commits To Dual Branded And Generic Model
CEO Maintains ‘World Class’ Generics Business And Innovative Interests Are Complementary
Teva’s innovative and generic interests can not only co-exist but are complementary, CEO Richard Francis has set out, in response to questions over whether the Israeli giant would consider splitting its businesses to focus more on branded drugs.
